Novartis Ag (NVS) Enterprise Value (2009 - 2026)
Novartis Ag (NVS) posted Enterprise Value of -$7.7 billion for Q2 2026, down 17.19% sequentially from -$6.6 billion in Q1 2026, and down 10.95% YoY from -$8.6 billion in Q2 2025.
Novartis Ag (NVS) Enterprise Value (2009 - 2026) Analysis & Trends
Novartis Ag has reported Enterprise Value for 18 years, with the latest figure at -$7.7 billion in Q2 2026.
- Quarterly Enterprise Value fell 10.95% year-over-year to -$7.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.7 billion (down 10.95% YoY) and the FY2025 annual result came in at -$11.2 billion, down 0.73% from the prior year.
- Enterprise Value eased to -$7.7 billion in Q2 2026 per NVS's latest filing, from -$6.6 billion in the prior quarter.
- Over five years, Enterprise Value peaked at $17.4 billion in Q2 2022 and troughed at -$18.8 billion in Q4 2022.
- A 5-year average of -$6.7 billion and a median of -$8.0 billion in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value soared 6941.57% in 2022, then slumped 632.3% in 2023.
- Over 5 years, Enterprise Value stood at -$18.8 billion in 2022, then soared by 32.79% to -$12.7 billion in 2023, then climbed by 9.94% to -$11.4 billion in 2024, then rose by 2.09% to -$11.2 billion in 2025, then surged by 31.16% to -$7.7 billion in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$7.7 billion, -$6.6 billion, and -$11.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.69 Bn |
| Mar 31, 2026 | -6.56 Bn |
| Dec 31, 2025 | -11.17 Bn |
| Sep 30, 2025 | 225.00 Mn |
| Jun 30, 2025 | -6.93 Bn |
| Mar 31, 2025 | -7.11 Bn |
| Dec 31, 2024 | -11.41 Bn |
| Sep 30, 2024 | -523.00 Mn |
| Jun 30, 2024 | -8.27 Bn |
| Mar 31, 2024 | -9.61 Bn |
| Dec 31, 2023 | -12.67 Bn |
| Sep 30, 2023 | -857.00 Mn |
| Jun 30, 2023 | -11.09 Bn |
| Mar 31, 2023 | -12.18 Bn |
| Dec 31, 2022 | -18.85 Bn |
| Sep 30, 2022 | 161.00 Mn |
| Jun 30, 2022 | 17.45 Bn |
| Mar 31, 2022 | -13.69 Bn |
| Dec 31, 2021 | -28.16 Bn |
| Sep 30, 2021 | -775.00 Mn |